drugset
drugset / Trial / NCT03243305

AMP002 Phase III Contraceptive Study

NCT03243305 ↗

Phase 3 Completed 1384 enrolled Evofem Inc. Parexel · collab
NaSingle-groupOpen-labelPrevention

Summary

This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.

Timeline

Start
2017-07-24
Primary completion
2018-11-29
Completion
2018-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject AMPHORA Unknown — Other

Indications

No indication recorded.